DrugPatentWatch Pharmaceutical Drug Patent Intelligence’s Post

https://lnkd.in/gXBSmirY Paper 32: Automated Decision Making ResNet Feed-Forward Neural Network based Methodology for Diabetic Retinopathy Detection

A double-blind clinical trial of 120 patients showed that topical use of Nigella Sativa has significantly better effects than synthetic drugs and placebo. Symptoms such as numbness, burning, and muscle cramps were significantly reduced. This natural option could be an effective solution without the side effects of conventional drugs. The results are promising for improving the quality of life of diabetic patients. Learn more about this topic on our website: https://lnkd.in/dGb_mUC3 If your company would like to create or manufacture a product indicated for neuropathic pain and neurological disorders in Diabetic Neuropathy, please contact us: info@farmaimpresa.it #DiabeticNeuropathy #NigellaSativa #TopicalTreatment #DiabeticHealth #ClinicalStudy #NaturalMedicine

What is #psychedelic medicine? They are #drugs that alter the perception of reality and are now being considered as therapies for a range of #mental and even physical #disorders. However, moving from #research to the #clinic presents massive challenges. Find out more: https://ow.ly/NnZZ50QanPb #clinicalresearch #drugresearch #psychedelicdrugs

The biomarker neurofilament light (NfL) has taken on a central role in neurology drug development, with drugs being approved or dropped based on what they do to NfL. We, like everyone, long assumed increases in NfL always meant neuronal damage, and decreases in NfL meant amelioration thereof. Today we report some data that have made us think there may be exceptions. In human, mouse, and cell culture we see NfL rise after minocycline treatment. The increase is very specific to NfL, has rapid washout kinetics distinct from neuronal injury, and does not seem to be associated with any neurotoxic signature. Our hypothesis: minocycline, by inhibiting microglial activity, may block clearance of NfL. Pre-print: https://lnkd.in/eQs_dzHM Blog post: https://lnkd.in/eTeqQ6yK Open data & source code: https://lnkd.in/ejT5cMed

Insilico Medicine heralds a medical breakthrough as its AI-created drug ISM5411 for IBD commences Phase I trials, offering hope for targeted gut barrier protection. @InSilicoMeds #IT #CIO #technology https://lnkd.in/ekGy52JG

Join this #GTC24 session to learn how Novartis is leveraging the Flywheel #AI Factory, for data ingestion and curation, annotation and labeling, model training and validation and inference. Discover how they're efficiently classifying optical coherence tomography images for macular degeneration and diabetic retinopathy. #healthcare #medicalImaging Shelby Wyatt Alex Benjamin

Join this #GTC24 session to learn how Novartis is leveraging the Flywheel #AI Factory, for data ingestion and curation, annotation and labeling, model training and validation and inference. Discover how they're efficiently classifying optical coherence tomography images for macular degeneration and diabetic retinopathy. #healthcare #medicalImaging Shelby Wyatt Alex Benjamin

Join this #GTC24 session to learn how Novartis is leveraging the Flywheel #AI Factory, for data ingestion and curation, annotation and labeling, model training and validation and inference. Discover how they're efficiently classifying optical coherence tomography images for macular degeneration and diabetic retinopathy. #healthcare #medicalImaging Shelby Wyatt Alex Benjamin

With more and more endpoints of trials measuring nfl and go/no go decisions depending on its level, we must aware the likely drawbacks of such nfl subservience

Lumanity and the PHARMO Institute for Drug Outcomes Research are partnering to deliver research insights into amyloidosis and its hard-to-identify subtypes, such as light chain (AL), amyloid (AA), and transthyretin amyloidosis (ATTR), and we invite you to put our data to the test. Our data is well-suited/ ready for conducting amyloidosis research with: - >10,000 patients with an amyloidosis related hospital admission or ambulatory consultation - Unique linkages to clinical labs and pathology data to uncover specific blood-based test results, biopsy, and gene sequences that point to clinical subtypes - Ability to address a range of RWE use cases from drug safety, treatment patterns, comparativeness effectives, clinical outcomes, and beyond Learn more about our expertise in Amyloidosis at https://buff.ly/48A5Pue and email us at contact@lumanity.com to discuss your research needs in amyloidosis. #amyloidosis #amyloidosisresearch #RWE #realworldevidence #drugsafety #ATTR